Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,830 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04450927Enrolling by invitation
Collecting health data from NHLBI patients and donors
This study collects information about standard care for people seen by the NHLBI, and also about donors. It helps researchers understand what happens in real-world care, which can improve future treatment decisions.
Bethesda, MarylandAges 2–120 - NCT04439916Recruiting
Preventing CMV after lung transplant in special donor/recipient pairs
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
Edmonton, AlbertaAges 18 years+ - NCT04410302Recruiting
Personalized tumor research for bladder, lung, stomach, and liver cancers
This study uses a small sample of your tumor to grow it in the lab, which may help researchers understand your cancer better and find treatments that work for you.
Orange, CaliforniaAges 21–100 - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04304820RecruitingPhase 2
Testing early oral cyclosporine and eltrombopag for severe anemia
This Phase 2 study tests whether starting two oral medicines early—cyclosporine and eltrombopag—can improve severe aplastic anemia in people who have not had prior treatment for it. It may help your blood counts recover without needing stronger or earlier treatments.
Bethesda, MarylandAges 3–99 - NCT04291755Enrolling by invitation
Stool bank for people receiving cancer immunotherapy
This study is building a “stool bank,” meaning they collect and store stool samples from people who are getting cancer immunotherapy. Researchers plan to analyze these samples to better understand cancer and treatment—your participation may help future research.
Fountain Valley, CaliforniaAges 18 years+ - NCT04273061RecruitingPhase 2
Atezolizumab for tumors that look sensitive on DNA/RNA testing
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Vancouver, British ColumbiaAges 18 years+ - NCT04263038RecruitingPhase 4
Watchful waiting versus blood thinners for small lung clots
This trial compares close monitoring (“watch and wait”) versus taking the blood thinner rivaroxaban in people with a small type of lung blood clot. It aims to find out whether low-risk patients can safely avoid or reduce anticoagulation while still staying healthy.
Woluwe-Saint-Lambert, Brussels CapitalAges 18 years+ - NCT04307615Recruiting
Oxygen versus CPAP during emergency lung fluid episodes
This trial tests whether regular oxygen or CPAP (a breathing-support machine) works better for people who have swimming-induced pulmonary edema, a sudden buildup of fluid in the lungs after swimming. It may help doctors choose the safest and most effective breathing treatment in an emergency.
FalunAges 18 years+ - NCT04307667Recruiting
Brain cell activity in mild asthma and allergies
This study looks at brain inflammation in people with mild asthma who are also allergic to common triggers like cats, dust mites, or ragweed. It uses MRI scans to see if a certain brain cell activity is different, which may help us understand asthma better and lead to new treatments.
Madison, WisconsinAges 18–75 - NCT04332367RecruitingPhase 2
New chemo plus ramucirumab for lung cancer after maintenance
This Phase 2 trial studies a combination of chemotherapy (carboplatin and a “taxane”) plus ramucirumab for people with advanced lung cancer that came back or progressed after prior maintenance treatment. It may help by attacking cancer growth after earlier therapy no longer worked.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT04354064Recruiting
Blood DNA test to see early treatment response in solid tumors
This study looks at circulating tumor DNA, which is tiny bits of DNA found in blood, to help assess how solid tumors are responding early. It uses blood samples from healthy adults who are willing to donate.
St Louis, MissouriAges 18 years+ - NCT01280994RecruitingPhase 2
Lung MRI test using special gas to measure breathing
This Phase 2 study uses a special type of MRI with inhaled gas to measure how well your lungs work. It may help researchers better understand lung function in healthy people and in people with lung disease.
Durham, North CarolinaAges 18 years+ - NCT04216342RecruitingPhase 1
Testing a new breathing-drug ingredient in healthy adults
This early study (Phase 1) tests how safe and tolerable Fx-5A is, and how the body processes it, in healthy volunteers. It’s mainly looking to understand side effects and drug levels rather than treating a disease.
Bethesda, MarylandAges 18–99 - NCT04190758Enrolling by invitation
Early arthritis study for RA, psoriatic arthritis, and psoriasis
This study looks at people with early arthritis related to rheumatoid arthritis, psoriatic arthritis, or psoriasis. Researchers want to understand how these early conditions behave and may help guide better treatment decisions.
GothenburgAges 18–80 - NCT04102423Recruiting
Study of CHIP and CCUS to track blood health changes
This study follows adults who have certain blood-cell DNA changes (CHIP or CCUS) to learn how their condition may progress over time. It mainly looks at natural history—what happens in the blood without giving an active treatment.
Bethesda, MarylandAges 18–99 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT04038619RecruitingPhase 1
Fecal transplant for immune-therapy diarrhea or bowel inflammation
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
Houston, TexasAges 18 years+ - NCT04098445Recruiting
Study of lung injury in children after stem cell transplant
This study follows children and teens who get a stem cell transplant to learn how lung problems develop over time. Your participation could help doctors better predict, prevent, and manage lung injury after transplant.
San Francisco, CaliforniaAges Up to 24 years - NCT04068012Recruiting
Test of a decision support tool for children with PARDS
This trial tests a computer “decision support” tool to help the care team manage treatment for children with PARDS who are just starting a breathing machine. It may help clinicians choose care steps and potentially support safer, more effective breathing management during the first days of ventilation.
Chicago, IllinoisAges 1 month–18 years - NCT04086082Recruiting
Marker-free X-ray guidance during lung radiotherapy
This study tests a way to guide lung radiation using X-ray images during treatment, without using implanted tracking markers for every step. It may help doctors target tumors more accurately while you receive external beam radiotherapy.
Melbourne, VictoriaAges 18 years+ - NCT03986034RecruitingPhase 2
Venetoclax study in relapsed CLL using early tumor tracking
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
Bethesda, MarylandAges 18–85
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,830 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.